A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical ...

DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. See why AZN stock is a Buy.

Patients were randomly assigned to calorie restriction with dapagliflozin 10 mg/day or placebo ... The study was partially ...

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...

Dapagliflozin (Farxiga, AstraZeneca) received approval based ... insulin or both were randomly assigned to 5 mg or 10 mg dapagliflozin, 2.5 mg or 5 mg saxagliptin, or placebo as an add-on ...

After that, Heerspink's group only continued with part B of the trial: zibotentan 1.5 mg plus dapagliflozin 10 mg/day and zibotentan ... The trial was funded by AstraZeneca. Some co-authors ...

for high dose (1.5 mg zibotentan / 10 mg dapagliflozin; n=179) and –27.0% (90% CI –38.4 to –13.6; p=0.002) for low dose (0.25 mg / 10 mg; n=91). The percentage mean change from baseline in ...

More than a decade after AstraZeneca appeared to give up hope ... A combo treatment of 1.5 mg zibotentan and 10 mg of the Big Pharma’s blockbuster CKD and diabetes drug Farxiga was shown to ...